the first monoclonal antibody to prevent infant syncytial virus has been launched in beijing and can be injected in infants under one year old
2024-09-26
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
the paper (www.thepaper.cn) learned from the ronghua community health service center in beijing economic and technological development zone that on september 24, a long-acting monoclonal antibody, a preventive measure against respiratory syncytial virus (rsv, hereinafter referred to as syncytial virus) for all infants, was launched at the ronghua community health service center in beijing economic and technological development zone and the sunhe community health service center in chaoyang district, beijing. these are the first batch of infants in beijing to receive the syncytial virus "vaccine" at the community vaccination clinic.
the first batch of infants at ronghua community health service center received the syncytial virus vaccination.
a pilot trial of monoclonal antibody for syncytial virus prevention was launched in beijing
respiratory syncytial virus is the most common and highly contagious respiratory virus in children and is the primary pathogen detected in infants and young children hospitalized for lower respiratory tract infections (mainly pneumonia and bronchiolitis). in northern my country, the peak epidemic period is usually in winter and spring (november to april of the following year).
on the 24th, ren kai, director of the health care section of the ronghua community health service center in beijing economic and technological development zone, said in an interview with the paper that syncytial virus infection mostly starts with upper respiratory tract infection, and the symptoms are similar to cold-like symptoms and are easily ignored by parents. in severe cases, syncytial virus can develop into lower respiratory tract infection, mainly manifested as bronchiolitis or pneumonia, with symptoms such as wheezing and dyspnea, coughing, shortness of breath, and hypoxia. "the progression of syncytial virus infection is relatively fast. in severe cases, it can develop into lower respiratory tract infection. infants with severe syncytial virus infection may have recurrent wheezing or asthma, which are manifestations of impaired lung function and may have long-term effects on children. we had no way to deal with this situation before, but now we have monoclonal antibodies, which are currently the best means of prevention."
in december last year, the national medical products administration approved the first domestic use of long-acting monoclonal antibody injection for respiratory syncytial virus, levitra® (nicevir monoclonal antibody injection), which is used to prevent or reduce lower respiratory tract infections caused by respiratory syncytial virus in newborns and infants. ren kai said that in recent years, more and more parents have become more aware of respiratory infectious diseases in infants and young children, and many parents have come to consult about long-acting monoclonal antibodies for syncytial virus.
wu qingrui, head of the planning and immunization department of the beijing economic and technological development zone center for disease control and prevention, introduced that the ronghua community health service center in the economic and technological development zone, as the first batch of pilot community immunization clinics, has formulated a work system based on relevant plans and laws and regulations of beijing, and can currently provide vaccination services for children aged 0-12 months.
"monoclonal antibody is indeed a rather special product. it is neither completely a medicine nor a vaccine in terms of classification. in terms of management and use, it is necessary to ensure that medical institutions have the qualifications for pediatrics and vaccination clinics. currently in beijing, the injection of monoclonal antibodies requires a prescription from a pediatrician and then the injection is carried out in an outpatient clinic. therefore, when selecting pilot units, we will consider those institutions that have both pediatrics and vaccination clinics." said wu qingrui.
with the arrival of flu season, the number of pediatric visits may increase significantly. not only should we pay attention to the vaccination of monoclonal antibodies, but we should also ensure the normal operation of pediatrics to avoid cross-infection between children with influenza and healthy children. ren kai introduced that the ronghua community health service center in the economic development zone has opened a separate clinic for pediatricians within the health care department, allowing them to consult and prescribe here, and guide parents to pay at the self-service machine in the health care department to reduce their flow in the hospital and reduce the risk of infection. "at the same time, we will also pay close attention to the visits to the pediatric department, adjust the staffing and work processes in a timely manner, and ensure the quality and safety of medical care." ren kai said.
the first batch of infants at sunhe community health service center received the syncytial virus vaccination.
now is a good time to inject syncytial virus monoclonal antibody
wu qingrui introduced that there are two ways to prevent diseases: passive immunity and active immunity. active immunity is to protect by awakening the body's immune system and stimulating its function. for example, vaccination is a kind of active immunity. vaccines introduce pathogens or some of their components into the body, stimulating the body to produce antibodies, thereby providing protection when encountering pathogens in the future. however, this process takes time. for example, it may take two to four weeks for the flu vaccine to produce effective antibodies.
passive immunity, on the other hand, is to inject antibodies directly into the human body, which can quickly provide protection. both methods have their own advantages and disadvantages. passive immunity takes effect quickly, but the effect may not last long. although active immunity takes a certain amount of time to take effect, once it takes effect, its protective effect is more lasting and can stimulate the development of the body's immune system.
"the syncytial virus monoclonal antibody we are currently using has a protection period of five to six months. this means that if it is injected before the peak of the respiratory syncytial virus epidemic, it can cover the entire peak period, that is, the winter and spring seasons, and provide effective protection for children." wu qingrui said.
like the flu vaccine, monoclonal antibodies can be injected throughout the respiratory disease epidemic season. ren kai said that as long as the child does not have clear symptoms of infection, monoclonal antibodies can be injected. of course, the earlier the antibody is injected, the earlier the protection can be obtained.
in addition, ren kai mentioned that in terms of adverse reactions, taking fever as an example, the incidence rate of fever is one in ten for general vaccine adverse reactions, while the incidence rate of fever adverse reactions for monoclonal antibodies is about five in a thousand.
wu qingrui also said that there is no need to wait between monoclonal antibodies and influenza vaccines. now is a good time to inject syncytial virus monoclonal antibodies because the flu season in beijing is about to begin. from the end of october and early november to march or april next year, it is the peak season for respiratory infectious diseases.
han yanrong, director of the ronghua community health service center in the economic and technological development zone, introduced that parents can go to the pediatrics and preventive health care departments for consultation, and make appointments on-site and through the official account to inject preventive monoclonal antibodies for their children.
the paper reporter zhang yilin
(this article is from the paper. for more original information, please download the "the paper" app)
